Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Confirmatory Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Topical HyBryte™ (Hypericin Sodium) and Visible-Light Activation for the Treatment of Cutaneous T-Cell Lymphoma (CTCL)

NCT06470451 is registered in ClinicalTrials.gov with Soligenix as lead sponsor.

NCT NCT06470451
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06470451 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Confirmatory Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Topical HyBryte™ (Hypericin Sodium) and Visible-Light Activation for the Treatment of Cutaneous T-Cell Lymphoma (CTCL)
Lead sponsor
Soligenix
Phase
Phase 3
Overall status
Terminated
Start date
January 7, 2025
Completion date
May 22, 2026
Enrollment
70 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

ctcl, ctcl/ mycosis fungoides, cutaneous t cell lymphoma, mycosis fungoides